Comment on

• A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.

  Semba CP, Torkildsen GL, Lonsdale JD, McLaurin EB, Geffin JA, Mundorf TK, Kennedy KS, Ousler GW. Semba CP, et al. Am J Ophthalmol. 2012 Jun;153(6):1050-60.e1. doi: 10.1016/j.ajo.2011.11.003. Epub 2012 Feb 11. Am J Ophthalmol. 2012. PMID: 22330307 Clinical Trial.
• A highly soluble matrix metalloproteinase-9 inhibitor for potential treatment of dry eye syndrome.

  Mori M, De Lorenzo E, Torre E, Fragai M, Nativi C, Luchinat C, Arcangeli A. Mori M, et al. Basic Clin Pharmacol Toxicol. 2012 Nov;111(5):289-95. doi: 10.1111/j.1742-7843.2012.00896.x. Epub 2012 May 18. Basic Clin Pharmacol Toxicol. 2012. PMID: 22520332
• Efficacy of topical blockade of interleukin-1 in experimental dry eye disease.

  Okanobo A, Chauhan SK, Dastjerdi MH, Kodati S, Dana R. Okanobo A, et al. Am J Ophthalmol. 2012 Jul;154(1):63-71. doi: 10.1016/j.ajo.2012.01.034. Epub 2012 Apr 26. Am J Ophthalmol. 2012. PMID: 22541929 Free PMC article.
• A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients.

  Takamura E, Tsubota K, Watanabe H, Ohashi Y; Diquafosol Ophthalmic Solution Phase 3 Study Group. Takamura E, et al. Br J Ophthalmol. 2012 Oct;96(10):1310-5. doi: 10.1136/bjophthalmol-2011-301448. Epub 2012 Aug 21. Br J Ophthalmol. 2012. PMID: 22914501 Free PMC article. Clinical Trial.
• A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye.

  Kinoshita S, Oshiden K, Awamura S, Suzuki H, Nakamichi N, Yokoi N; Rebamipide Ophthalmic Suspension Phase 3 Study Group. Kinoshita S, et al. Ophthalmology. 2013 Jun;120(6):1158-65. doi: 10.1016/j.ophtha.2012.12.022. Epub 2013 Mar 13. Ophthalmology. 2013. PMID: 23490326 Clinical Trial.